Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYDRO: Amlitelimab on Vaccine Antibody Responses in Atopic Dermatitis
NCT06015308Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of amlitelimab in atopic dermatitis (AD), sponsored by Sanofi. Started Oct 2023; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06015308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015308.